Ibrutinib, Brentuximab, Blinatumomab da Idelalisib
Cibiyar Harkokin Halittar {asashen Amirka (ASH) ita ce mafi yawan masana'antun masana'antu ta duniya da ke damuwa da mawuyacin cutar da jini. Kowace shekara, mafi kyau kuma mai haske daga ko'ina cikin duniya ya halarci ASH.
A wannan shekara, akwai lokuta game da sababbin hanyoyin magance hanyoyin FDA don yanayin yanayin jini. Ana gudanar da shi saboda 'yan asibiti sun buƙaci ƙarin bayani game da wasu takardun shaida na FDA.
Masu magana sun sake nazari da dama game da sababbin kwayoyi, ciki har da ibrutinib (Imbruvica), da idelalisib (Zydelig).
Ga mutane da yawa, taron na Disamba na ASH ya zama abin kwaikwayo don dukan ci gaban da aka yi a cikin shekarar da ta gabata a cikin ilimin halayyar jini da ilimin halitta. Ga wasu 'yan abubuwan da mutane ke magana game da su.
Ibrutinib (Imbruvica)
Daban sunadarai daban-daban ko ƙananan abubuwa, irin su enzymes, suna da rawar a cikin siginar siginar-tsarin da abin da kwayoyin ke "saurara" da kuma amsawa ga sakonni sunadarai. Bruton's Tyrosine Kinase (BTK), wani enzyme wanda ke taka muhimmiyar rawa a ci gaban B-cell, misali ne irin wannan enzyme wanda ke sarrafa siginar salula. Ibrutinib wani karamin kwayoyin ne wanda ke kaddamar da BTK enzyme.
Ta hanyar hana wannan enzyme, ibrutinib yana shawo kan hanya mai nuna alama da wasu kwayoyin cutar kanjamau suke dogara. Bisa ga nasarorin da aka samu a yanzu, FDA ta sanya Ibrutinib a matsayin farfadowa, tare da taka muhimmiyar rawa wajen magance wadannan malignancies:
- Likitan cutar ciwon sankarar lymphocytic na zamani (CLL) marasa lafiya wanda ya karbi akalla daya kafin magani
- Magungunan cutar sankarar jini lymphocytic na zamani (CLL) tare da sharewa 17p
- Sugar lymphoma cellular (Mantle cell lymphoma) wadanda suka karbi akalla daya kafin magani
Ibrutinib wani kwaya ne wanda aka dauka sau ɗaya a rana kuma yana da kyau a jure shi. Amfani da wakili kuma ana bincika a kan maganin wasu cututtuka, duka biyu kuma a hade tare da hanyoyin shan magani daban-daban.
Idelalisib (Zydelig)
Idelalisib shi ne FDA-an yarda da mutanen da suka kamu da cutar cutar sankarar lymphocytic na kullum (CLL) , sun sake yin amfani da lymphoma lymphoma lymphoma (SLL), watau LL, wani nau'in lymphoma ba Hodgkin.
Amincewa ta dogara ne akan binciken da aka samu a cikin marasa lafiya 220 tare da CLL, inda ba a tsara tsarin chemotherapy ba. Tsarin ya kasance ko idelalisib + rituximab ko placebo + rituximab. Shari'ar ta nuna kashi 82% a cikin hadarin cigaba da ciwon ciwon daji tare da idelalisib, saboda haka sun dakatar da shi da wuri, suna barin masu sanadiyar wuribo + rituximab sun san kome game da idelalisib kuma suna ba su sabuwar magani. Dukkan marasa lafiya a cikin rukuni na rituximab + inda aka fara samun idelalisib.
Brentuximab vedotin (Adcetris)
Wannan wakili ne mai allura don jigilar intravenous. Brentuximab vedotin yana da matukar ban sha'awa na aikin. Yana da wani mutum ne wanda aka kirkiri - an hada shi tare da wani wakili wanda ke taimakawa wajen kashe ciwon daji lokacin da suka kai ga manufa. An ƙaddara shi ne ga furotin da ake kira CD30, wanda yake a cikin lymphoma Hodgkin na Hodgkin (HL) kuma a cikin lymphoma cell cell anaplastic (sALCL).
Nazarin da aka tattauna a ASH shi ne na farko a lymphoma don nuna cewa kara da magungunan maganin bayan da aka dasa shi zai iya inganta sakamakon haƙuri.
A cikin gwajin AETHER, game da kashi 63 cikin 100 na marasa lafiya na lymphoma mai tsanani da aka bi da su tare da miyagun ƙwayoyi sun sami zaman rayuwa mai sauƙi mai rai 24 da idan aka kwatanta da 51% na marasa lafiya da suka sami placebo.
Blinatumomab (Blincyto)
Wannan miyagun ƙwayoyi ne na farko na magungunan BITE (Bi-specific T Cell Engager) da za a yarda. Ya nuna muhimmancin aiki a cikin ƙwayar cutar ta cutar sankarar bargo a cikin kwayar cutar B-cell (ALL) marasa lafiya tare da ƙananan ciwon daji bayan jijiyar induction , a cewar masu bincike a ASH. Blinatumomab ya wanke kwayoyin cutar ciwon daji daga kashi 78% na marasa lafiya 112.
A cewar Cibiyar Cancer ta Kasa, blinatumomab ita ce mai amfani da fasaha wanda zai iya taimakawa wajen samar da tsarin rigakafin da kuma ci gaba da ciwon daji tare da ayyukan maganin maganin rigakafi.
FDA ta amince da blinatumomab don magance marasa lafiya tare da Philadelphia chromosome -ƙananan ƙwayoyin cutar B-cell lymphoblastic leukemia (B-cell ALL), wani nau'i na al'ada ALL.
Duba Niccola Gokbuget, MD, bayyana yadda blinatumomab ke aiki.
CARs da ke kaiwa ga KASA KASA
Bayanan lokaci mai tsawo daga fitina ta amfani da siginar antigen receptor (CAR) T sun nuna wadannan kwayoyin halitta sun tsaya a ciki na dan lokaci, yin aikin su, suna haifar da gafartawa mai zurfi. Mutane da yawa a cikin masana kimiyya sunyi tsammanin irin wannan farfadowa na musamman don magunguna daban-daban waɗanda suke da wuya a ɗauka.
Lura a kan Hannun Yankuna
Na bayanin kula, duk waɗannan masu lakabi suna da illa mai laushi, wasu daga cikinsu na iya zama mai tsanani, kuma wasu daga cikin waɗanda ba su sani ba tukuna. Kamar yadda dukkanin magunguna suke, shawarar da za a bi da shi yana shafar abin da aka sani game da hadarin da ke tattare da magani da kuma dalilai masu haƙuri.
Sources
Cibiyar Cancer ta Kasa. Bayanan lafiyar Blinatumomab. http://www.cancer.gov/drugdictionary?cdrid=487684. An shiga watan Disambar 2014.
MedPageToday. http://www.medpagetoday.com/MeetingCoverage/ASHHematology/48998. An shiga watan Disambar 2014.